A Phase 1 interventional study of Sitagliptin phosphate/metformin hydrochloride FDC and Sitagliptin phosphate in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-08-13.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 123rd largest by enrollment of the 197 interventional ones that give a count, is one of 23 that started in 2008, is one of 23 in phase 1, and was the 70th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–65
Bahria University · Sites in Pakistan
Ages 30–55
Yonsei University · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 11 · Phase 3 74 · Phase 4 68
First in 2003; this study’s year is marked. 23 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 61 is below the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 102 across the 197 interventional studies. Of the 172 that completed or were terminated, 117 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 198 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 118th largest by enrollment of the 170 interventional ones that give a count, is one of 26 that started in 2008, is one of 55 in phase 1, and was the 82nd registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will demonstrate the bioequivalence of metformin after single dose administration of sitagliptin/metformin 50/500 mg fixed dose combination (FDC) tablet and concomitant administration of single doses of sitagliptin 50 mg and metformin 500 mg as individual tablets after consumption of a high-fat meal.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants receive sitagliptin (Sita) 50 mg and metformin (Met) 500 mg individual tablets administered concomitantly as a single dose during Period 1 followed by a 7-day washout followed by sitagliptin/metformin (Sita/Met) 50/500 mg FDC tablet administered as a single dose during Period 2.
Drug: Sitagliptin phosphate/metformin hydrochloride FDC · Drug: Sitagliptin phosphate · Drug: Metformin hydrochloride
Participants receive sitagliptin/Metformin 50 mg/500 mg FDC tablet administered as a single dose during Period 1 followed by a 7-day washout followed by sitagliptin 50 mg and metformin 500 mg individual tablets administered concomitantly as a single dose during Period 2.
Drug: Sitagliptin phosphate/metformin hydrochloride FDC · Drug: Sitagliptin phosphate · Drug: Metformin hydrochloride
Drug pages: Sitagliptin · Metformin
Single dose sitagliptin/metformin 50/500 mg FDC tablet after consumption of a high-fat meal in one of two treatment periods.
Single dose sitagliptin 50 mg tablet after consumption of a high-fat meal in one of two treatment periods.
Single dose metformin 500 mg tablet after consumption of a high-fat meal in one of two treatment periods.
Plasma Area Under the Curve (AUC(0 to Infinity)) for Metformin
Serum samples were used to determine the AUC from time 0 to infinity for metformin.
Time frame: Predose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 32, 48, and 72 hours postdose
Peak Plasma Concentration (Cmax) of Metformin
Serum samples were used to determine the maximum concentration for metformin.
Time frame: Predose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 32, 48, and 72 hours postdose
| Milestone | Sita + Met Then Sita/Met FDC | Sita/Met FDC Then Sita + Met |
|---|---|---|
| Started | 30 | 31 |
| Completed | 30 | 30 |
| Not completed | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Milestone | Sita + Met Then Sita/Met FDC | Sita/Met FDC Then Sita + Met |
|---|---|---|
| Started | 30 | 30 |
| Completed | 30 | 30 |
| Not completed | 0 | 0 |
| Milestone | Sita + Met Then Sita/Met FDC | Sita/Met FDC Then Sita + Met |
|---|---|---|
| Started | 30 | 30 |
| Completed | 30 | 30 |
| Not completed | 0 | 0 |
Serum samples were used to determine the AUC from time 0 to infinity for metformin.
| μg * hr/mL | Sita + Met | Sita/Met FDC |
|---|---|---|
| Plasma Area Under the Curve (AUC(0 to Infinity)) for Metformin | 7.65 ± 1.39 | 7.45 ± 1.48 |
Serum samples were used to determine the maximum concentration for metformin.
| ng/mL | Sita + Met | Sita/Met FDC |
|---|---|---|
| Peak Plasma Concentration (Cmax) of Metformin | 929 ± 181 | 887 ± 187 |
Collected over Up to 24 days (including 14 days after administration of study drug in the last treatment period). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sita + Met | — | 0/60 (0%) | 2/60 (3.3%) |
| Sita/Met FDC | — | 0/61 (0%) | 6/61 (9.8%) |
| Event | Sita + Met | Sita/Met FDC |
|---|---|---|
| HeadacheNervous system disorders | 2/60 | 6/61 |
| Age, Continuous(Years) | All Participants |
|---|---|
| Mean | 32.4 (18 to 45) |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 32 |
| Male | 29 |
| Height(Centimeters) | All Participants |
|---|---|
| Mean | 164.9 (150.0 to 184.0) |
| Weight(Kilograms) | All Participants |
|---|---|
| Mean | 73.0 (45.9 to 102.3) |
No study locations are listed for this record.
The record gives a start of Jan 2008, a primary completion of Mar 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2010, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sitagliptin · Metformin